Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market Analysis and Forecast

Growing Disease Prevalence Fueling the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market 

The rising global incidence of atherosclerosis, diabetes, hypertension, and smoking-related vascular damage has led to an unprecedented surge in the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market. Peripheral Arterial Disease, affecting over 200 million people globally, is increasingly being recognized as a major public health burden. In nations with aging populations, such as Japan and many European countries, PAD is diagnosed at significantly higher rates, resulting in an escalated demand for advanced therapeutic interventions. 

The increasing prevalence of diabetes is a critical driver. For instance, with over 537 million adults living with diabetes in 2021—a number projected to reach 783 million by 2045—the incidence of PAD, a common complication of long-standing diabetes, is expected to rise substantially. This epidemiological trend has spurred major pharmaceutical players to expand their investment into the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market, aiming to develop innovative drugs targeting both early and advanced stages of vascular occlusion. 

 

Technological Innovations Boosting the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market 

Technological advancements in drug formulation and targeted delivery systems are significantly transforming the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market. Novel approaches such as lipid nanoparticle delivery systems, siRNA-based therapies, and sustained-release pharmacokinetics are being incorporated into pipeline assets to enhance efficacy and minimize systemic side effects. 

For example, the adoption of drug-coated balloons and localized delivery of antiproliferative agents, like paclitaxel and sirolimus, has influenced the oral drug pipeline to mirror localized, potent intervention strategies. As pharmaceutical R&D shifts toward highly targeted vascular therapies, the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market is witnessing robust expansion of preclinical and early-phase assets adopting similar precision-focused paradigms. 

 

Strategic Collaborations Enhancing Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market Development 

Strategic partnerships between biotechnology firms and contract research organizations (CROs) have emerged as a critical trend shaping the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market. Collaborations are facilitating accelerated drug development timelines and expanding the geographic reach of clinical trials. 

For instance, alliances focusing on combination therapies involving antiplatelet agents, cholesterol-lowering drugs, and anti-inflammatory molecules are contributing to a dynamic and differentiated pipeline. Such partnerships not only bring financial investment but also technical expertise in trial design, regulatory navigation, and patient recruitment—core elements that are pushing the pipeline from preclinical discovery to late-stage development at a more accelerated pace. 

 

Clinical Trial Expansion Driving the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market 

The widening scope of clinical trials targeting PAD/PVD therapeutics is playing a pivotal role in expanding the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market. There is an observable increase in Phase II and Phase III studies focusing on novel anti-inflammatory and endothelial-stabilizing agents. Many of these drugs aim to go beyond symptomatic relief and offer disease-modifying benefits, such as reducing limb ischemia progression and minimizing major amputations. 

For example, experimental drugs focusing on P-selectin inhibition or VEGF modulation have moved forward in clinical evaluation, signaling a shift toward molecular pathway–based therapeutics. The increasing number of trials recruiting patients with moderate to severe PAD, especially in high-risk populations, is enhancing data richness and reinforcing the market’s potential to support diverse therapeutic classes. 

 

Personalized Medicine Elevating the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market 

Personalized medicine is beginning to reshape the landscape of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market. With advances in genomics and patient stratification, developers are moving toward precision-targeted therapies tailored to individuals’ genetic and metabolic profiles. 

For instance, certain patients exhibit a heightened thrombotic response due to specific polymorphisms in platelet receptors or clotting proteins. Drugs in the pipeline are increasingly being designed to address these biological variations, thereby improving therapeutic outcomes and minimizing adverse events. The introduction of pharmacogenomics into PAD/PVD drug development is creating new sub-segments within the market, each with distinct regulatory, clinical, and commercial pathways. 

 

Economic Burden and Unmet Needs Pushing Growth in the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market 

The high economic burden associated with Peripheral Arterial Disease is a significant factor driving the expansion of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market. Hospitalizations due to critical limb ischemia, revascularization procedures, and amputations contribute to significant healthcare costs globally. 

For instance, in the United States alone, the total annual cost associated with PAD is estimated to exceed $21 billion. This economic impact highlights a significant unmet need in therapeutic innovation. Consequently, pharmaceutical companies are responding with a diversified drug development approach, aiming to reduce long-term complications and hospital resource use, thereby making the pipeline more attractive to both investors and healthcare systems. 

 

Regulatory Support Accelerating Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market Progression 

The regulatory environment is gradually becoming more supportive of innovation in the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market. Agencies are increasingly recognizing PAD as a serious, often underdiagnosed condition, warranting expedited review and orphan drug incentives for specific high-risk subgroups. 

For example, fast-track and breakthrough therapy designations are being granted to candidates demonstrating substantial improvements over existing treatments in early trials. These regulatory mechanisms not only lower development barriers but also offer a competitive edge to early movers, encouraging a broader range of pipeline entries and propelling the overall market momentum. 

 

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market Size Driven by Rising Demand for Non-Surgical Interventions 

The Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market Size is witnessing substantial growth, primarily due to the increasing demand for pharmacological alternatives to surgical and catheter-based interventions. While procedures like angioplasty and stenting remain common, many patients—especially those with comorbidities—are either ineligible or reluctant to undergo invasive treatments. 

This shift is creating a favorable environment for the development of oral, injectable, and topical drugs targeting vascular inflammation, thrombosis, and endothelial dysfunction. As the aging population continues to grow and seeks non-invasive solutions, the demand for effective PAD/PVD medications is expected to rise, further enhancing the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market Size. 

 

Competitive Landscape Intensifying Within the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market 

The competitive dynamics of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market are intensifying as new entrants and legacy pharmaceutical firms alike compete to claim first-to-market advantages. Companies are targeting multiple mechanisms of action, ranging from antithrombotic to vasodilatory and anti-inflammatory pathways. 

Furthermore, the rise in venture capital and private equity funding toward PAD-focused biotech startups is amplifying innovation and encouraging the exploration of previously untargeted molecular pathways. With numerous candidates currently in preclinical and early clinical stages, the next five years are expected to see a marked increase in regulatory filings, launch activities, and commercialization efforts. 

 

North America Leading in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market 

The Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market in North America continues to maintain its leadership position due to a combination of high disease prevalence, advanced healthcare infrastructure, and robust investment in pharmaceutical R&D. The United States, in particular, accounts for a disproportionately large share of global PAD-related healthcare spending. For instance, more than 8.5 million people in the United States are diagnosed with PAD, with a majority aged over 60. This demographic trend directly contributes to the heightened Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), demand across therapeutic classes. 

Datavagyanik observes that the presence of leading pharmaceutical companies and a favorable regulatory environment are key enablers driving the early-stage development and clinical testing of novel PAD/PVD drug candidates in this region. Companies are actively utilizing accelerated approval pathways and orphan drug designations, pushing forward the pipeline with unprecedented speed and scale. As the number of clinical trials in vascular diseases grows, North America’s dominance in the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market is expected to remain resilient through 2030. 

 

Europe Emerging as a Dynamic Market for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Demand 

Europe represents a critical growth frontier for the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market, driven by an aging population, increased screening rates, and public health campaigns focused on early intervention. Countries such as Germany, the United Kingdom, France, and Italy have reported substantial increases in PAD diagnosis rates, particularly among diabetic and hypertensive patients. 

For example, Datavagyanik highlights that Germany has over 4 million PAD patients, with a rising share being classified in advanced Fontaine stages. This growing clinical burden has triggered a proportional rise in demand for pharmacological management solutions, including antithrombotic, lipid-lowering, and endothelial-targeted drugs currently under development. Furthermore, European regulatory authorities are expanding support for investigator-led studies and real-world evidence collection, further catalyzing the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), demand in this region. 

 

Asia-Pacific Driving Volume Growth in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market 

The Asia-Pacific region is witnessing the fastest growth in the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market, primarily due to increasing lifestyle-related disorders and expanding healthcare access. Countries like China and India are experiencing a sharp rise in PAD incidence, attributed to surging rates of diabetes, tobacco use, and sedentary lifestyles. For instance, China alone houses over 100 million diabetics, a significant portion of whom are at risk of developing PAD, thereby triggering massive demand for targeted drug therapies. 

Datavagyanik emphasizes the strategic entry of multinational drug developers into Asia-Pacific markets through licensing deals, regional clinical trials, and local partnerships. As awareness around PAD/PVD improves and government healthcare expenditure continues to rise, especially in urban and tier-2 cities, the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market is set to benefit from enhanced volume-driven growth in the coming decade. 

 

Latin America and Middle East Showing Nascent Yet Promising Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Demand 

While still in early stages of market maturity, Latin America and the Middle East are beginning to exhibit increased Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), demand, driven by evolving epidemiological patterns and improved diagnosis rates. For instance, Brazil and Saudi Arabia have recorded noticeable increases in PAD-related outpatient visits over the past five years, largely due to rising awareness among general practitioners and the availability of Doppler ultrasound diagnostic services in both public and private hospitals. 

Datavagyanik identifies infrastructure gaps and pricing barriers as short-term challenges; however, the influx of generic and biosimilar pipeline drugs in these markets could drastically improve access. Local clinical collaborations and government support for non-communicable disease management are expected to uplift market readiness and encourage further expansion of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market across these emerging economies. 

 

Market Segmentation Expanding Scope of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market 

The Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market is becoming increasingly segmented based on drug class, mechanism of action, disease stage, and patient profile. For instance, there is growing differentiation between drugs targeting early-stage intermittent claudication and those intended for critical limb ischemia. This segmentation is facilitating more precise targeting of clinical needs, creating multiple market entry points for pharmaceutical developers. 

Drug classes in focus include antiplatelet agents, anticoagulants, vasodilators, anti-inflammatories, and angiogenesis promoters. Datavagyanik notes that certain pipeline drugs are being positioned to cater to niche sub-segments such as diabetic PAD patients, elderly individuals with multi-morbidity, and patients contraindicated for surgical interventions. The diversity in mechanisms—ranging from nitric oxide modulation to selective cytokine inhibition—is further broadening the reach of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market. 

 

Oral and Injectable Formulations Reshaping Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Demand 

Within product type segmentation, oral and injectable formulations are becoming increasingly relevant in the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market. Oral drugs offer ease of administration and high patient compliance, particularly in elderly populations managing multiple comorbidities. For instance, oral antiplatelet agents under development are being designed for once-daily dosing with enhanced bioavailability and reduced gastrointestinal risk. 

Injectables, on the other hand, are gaining traction in the hospital setting, especially for acute management of ischemic events. Novel subcutaneous formulations designed for outpatient self-administration are entering early clinical stages, targeting patients at high risk of acute thrombotic events. Datavagyanik observes that the increasing innovation in delivery mechanisms is directly contributing to Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), demand across healthcare settings. 

 

Hospital and Specialty Clinics Driving Distribution in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market 

Hospital pharmacies and specialty vascular clinics continue to dominate the distribution landscape in the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market. For example, a majority of injectable therapies and early access drugs are administered in clinical settings under close monitoring. The increasing trend of establishing dedicated vascular medicine departments within tertiary hospitals is boosting demand for both investigational and approved PAD/PVD drugs. 

Datavagyanik highlights that outpatient cardiology centers are also beginning to play a larger role in managing moderate PAD cases using pipeline therapies under compassionate use programs. This expansion of treatment access points is expected to drive Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), demand in non-hospital environments, enhancing market penetration among underserved populations. 

 

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market Price Trend Reflecting Innovation and Risk 

The pricing structure within the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market is influenced by multiple variables, including R&D complexity, targeted disease stage, and route of administration. Innovative drug candidates with unique mechanisms of action—such as gene therapies or siRNA-based agents—are entering the pipeline with high projected price tags, reflecting both development cost and potential outcome improvements. 

For instance, Datavagyanik notes that Phase III drugs aiming to prevent limb amputation in critical limb ischemia patients are expected to command premium pricing, especially if they demonstrate long-term reduction in revascularization procedures. On the other hand, reformulated generics and biosimilars targeting early-stage PAD symptoms are expected to enter the market at competitive price points, improving accessibility in price-sensitive regions. 

 

Balancing Cost and Value in the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market 

Value-based pricing is becoming a key consideration in the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market. Payers are increasingly scrutinizing clinical endpoints such as improvement in walking distance, reduction in hospitalization, and delayed progression to critical stages before committing to high-cost therapies. This dynamic is pushing drug developers to demonstrate not just efficacy but also long-term value through health economic outcomes research. 

Datavagyanik underscores the importance of cost-efficiency, particularly in publicly funded healthcare systems. Pharmaceutical companies are responding by investing in real-world studies and payer collaboration programs to align drug pricing with actual patient benefit, thereby sustaining Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), demand while navigating reimbursement barriers. 

 

Key Players Shaping the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market 

The Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market is defined by the active involvement of leading multinational pharmaceutical corporations, biotechnology innovators, and emerging clinical-stage companies. These market participants are shaping the competitive landscape through product innovation, strategic acquisitions, and aggressive pipeline expansion. 

At the forefront of the market is Bayer AG, which commands a significant share of the PAD drug market through its anticoagulant Xarelto (rivaroxaban). While already approved, Bayer continues to explore expanded indications and combination therapies, particularly for high-risk PAD patients. The company’s continued investment in vascular thrombosis R&D positions it as a dominant force in the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market. 

Another major player is AstraZeneca, which is developing targeted anti-inflammatory treatments for PAD/PVD. One of its lead investigational candidates includes Ziltivekimab, an IL-6 inhibitor, which is undergoing clinical evaluation for cardiovascular risk reduction, including in PAD patients. AstraZeneca is leveraging its cardiovascular pipeline strength to diversify its vascular portfolio, pushing into early disease-modifying approaches in PAD. 

 

Emerging Biotech Firms Reshaping the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market 

Innovative biotech companies are making considerable strides in reshaping the early-phase segment of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market. Firms such as Cereno Scientific and AtheroNova are exploring epigenetic modulators and lipid-lowering mechanisms to reduce plaque formation and promote vascular repair. Cereno’s investigational product CS1, a histone deacetylase inhibitor with antithrombotic potential, is being positioned as a first-in-class drug for rare vascular conditions and has crossover potential into PAD segments. 

XORTX Therapeutics, while traditionally focused on kidney and metabolic diseases, is entering the PAD/PVD space with uric acid–modulating therapies aimed at improving endothelial health and mitigating microvascular damage. These developments reflect a strong pipeline presence among smaller players who are bringing targeted innovations to market and creating potential acquisition interest from large pharma. 

 

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market Share Dynamics 

Market share in the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market is currently concentrated among a handful of large companies, although this landscape is expected to shift significantly over the next five to seven years. Presently, Bayer, AstraZeneca, and Bristol-Myers Squibb together control over 40% of the therapeutic space due to strong commercial performance of antithrombotic agents such as Xarelto and Eliquis (apixaban). 

However, Datavagyanik anticipates a gradual erosion of this dominance as novel therapeutic classes enter late-stage trials and move toward approval. For instance, Janssen Pharmaceuticals, a Johnson & Johnson company, is conducting trials on combination therapies involving factor Xa inhibitors and antiplatelet drugs, aiming to capture a differentiated PAD segment and expand its existing footprint in vascular diseases. 

Another notable player, Amgen, is focusing on lipid reduction and plaque stabilization. Its investigational therapies, including olpasiran, an Lp(a)-targeting siRNA, have potential application in advanced atherosclerotic disease, indirectly addressing PAD/PVD patient groups. Amgen’s long-standing experience in cardiometabolic diseases may allow it to carve out a meaningful share of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market once these assets mature. 

 

Focused Product Pipelines Accelerating Competitive Differentiation 

Companies are increasingly differentiating their pipeline strategy by targeting specific stages or subtypes of PAD. For instance, Reflow Medical, primarily known for its peripheral devices, is working in collaboration with pharma companies to evaluate drug-device combinations. These include drugs that can be delivered intraluminally to prevent restenosis and encourage vascular remodeling post-angioplasty. 

Another focused pipeline comes from Cynata Therapeutics, developing mesenchymal stem cell–based therapies to repair ischemic tissue in critical limb ischemia patients. The company’s lead candidate, CYP-002, is being positioned for severe PAD with no viable surgical option. If successful, it would represent a paradigm shift in PAD treatment and open an entirely new category of regenerative therapeutics within the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market. 

 

New Market Entrants Intensifying Competition in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market 

Several new entrants are increasing the depth of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market. Companies such as Verve Therapeutics and Silence Therapeutics are exploring gene-editing and RNA interference strategies respectively, aiming to address the root causes of atherosclerosis and vascular inflammation, which are central to PAD development. 

These entrants are leveraging next-generation technology platforms to build highly targeted solutions with the potential for single-dose or long-duration efficacy. While their commercial entry may be a few years away, their disruptive pipeline presence is already attracting investor attention and altering the long-term growth projections for the market. 

 

Recent Developments in Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market 

The Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market has witnessed several significant developments in recent quarters, signaling accelerated innovation and regulatory momentum. 

• In Q1 2025, AstraZeneca expanded its PAD research arm to include combination studies of Ziltivekimab with existing antiplatelet regimens. This signals a broader strategic move toward integrated vascular care solutions. 

• In April 2025, Bayer announced positive mid-stage trial results of a new oral factor XIa inhibitor, aimed at reducing thrombotic events in PAD patients without increased bleeding risk. The drug is expected to move into Phase III by early 2026. 

• In May 2025, a partnership between Amgen and Verve Therapeutics was formed to co-develop gene-editing drugs for atherosclerotic cardiovascular diseases, with early indications of applicability in PAD populations. 

• Cynata Therapeutics reported successful preclinical results in June 2025 for CYP-002, showing improved perfusion and tissue regeneration in animal models of critical limb ischemia, setting the stage for Phase I trials in 2026. 

• Janssen Pharmaceuticals, in July 2025, initiated global trials of a dual-pathway therapy that combines low-dose rivaroxaban and P2Y12 inhibitors in high-risk PAD patients with diabetes, a group historically underserved by current treatments. 

These developments are reinforcing the vibrancy and competitive intensity of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Drugs Pipeline (Under Development), Market, with new modalities, broader indications, and more personalized approaches being actively pursued. 

 

Key Insights that the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)  Market analysis report presents are:

• Break-down of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)  drugs under development in terms of application areas, target customers, and other potential market segments
• Areas that are relatively more potential and are faster growing
• Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)  Market competitive scenario, market share analysis
• Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)  Market business opportunity analysis

Global and Country-Wise Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)  Market Statistics

• Global and Country-Wise Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)  Market Size ($Million) and Forecast, till 2030
• Global and Country-Wise Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)  Market Trend Analysis
• Global and Country-Wise Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)  Market Business Opportunity Assessment